ArticleImmunity & ageing : I & A2025
Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection.
Article in Immunity & ageing : I & A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Galectin Family in Colorectal Cancer: Integrating Molecular Mechanisms with Diagnostic, Prognostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- A Circulating Signature of Tumour Hybrid Cells and Immune Checkpoints Predicts Metastatic Progression in Lung Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Ageing is a well-recognised factor influencing immune competence; however, elderly individuals remain underrepresented in clinical trials, resulting in gaps in our understanding of their immune responses to disease. To address this gap, we investigated circulating soluble immune checkpoints (sICs) and cytokines in the elderly and middle-aged individuals, both healthy and patients with colorectal cancer (CRC). Our findings revealed a decline in sICs and cytokine levels in healthy elderly individuals compared to their middle-aged counterparts. Key analytes -Galectin-9, sLAG-3, sPD-L1 and sTIM-3- effectively distinguished age groups in healthy volunteers (HVs). However, these differences were not observed when applying this signature in CRC patients, where the combined analysis of plasma Galectin-9, IL-10 and CXCL10 did reliably discriminate between elderly CRC patients and age-matched HVs. This result highlights the potential of these immunological factors as non-invasive biomarkers for cancer detection in this population. In contrast, a much larger number of soluble markers was needed to distinguish CRC patients from HVs among the middle-aged. Collectively, these findings underscore the relevance of observing age stratification for biomarker discovery and lay the groundwork for further exploration of soluble immune mediators in ageing related to tumour pathophysiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.